



Modular Program Report

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview	
Request Description	<p>As a follow-up request to MPR17, FDA has requested execution of Modular Program #3 to investigate the use of Buprenorphine products both separately and as one drug category among all members (Overall) as well as those with a pre-existing diagnosis found in one of three composite categories: addiction-related diagnoses (16 codes), pain-related diagnoses (22 codes), and other defined diagnoses (8 codes). A user may be counted in more than one category. The time window for the request is January 1, 2009 through December 31, 2010. The program was run a total of 24 times (2 drug groups x 3 time periods x 4 pre-existing condition groups) against the Mini-Sentinel Distributed Database and was distributed on February 15, 2011.</p> <p>Results provide counts of incident users, dispensings, and total days supplied of Suboxone, Subutex, Buprenex, Butrans, Generic Oral Buprenorphine, Generic Injectable Buprenorphine, Generic Powder Buprenorphine, and all Buprenorphine products. A washout period of 0 days was used to estimate prevalent use. The maximum allowable treatment gap was set to 14 days, and the minimum episode duration and the minimum episode days supplied were set to zero days. The program was run for all users as well as those with pre-existing diagnosis codes falling into one of three groups: addiction, pain, or other. The pre-existing condition lookup period was set at 90 days from the drug index date.</p> <p>Please review the Notes below and refer to the Modular Program request for request specifications.</p>
Request ID	MSY3_MPR2
Specifications	Program specifications
Table 1	Number and Percent of New Users by Drug Product and Pre-Existing Condition Category for each Year/Period - Note: There is no Figure 1 associated with Table 1
Table 2	Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Pre-Existing Condition Category, Drug Product, Age Group, and Sex
Table 3	Number of New Users, Dispensings, and Total Days Supplied in 2009 by Pre-Existing Condition Category, Drug Product, Age Group, and Sex
Table 4	Number of New Users, Dispensings, and Total Days Supplied in 2010 by Pre-Existing Condition Category, Drug Product, Age Group, and Sex
Table 5	Number of New Users and Enrollees as well as Number of New Users per 100,000 Enrollees by Data Partner, Year/Period, Pre-Existing Condition Category, and Drug Product
Notes:	Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Modular Program Specifications

Modular Program #3 was used to investigate the use of Buprenorphine products both separately and as one drug category among all members as well as those with pre-existing addiction-related, pain-related diagnoses, and other defined diagnoses. Three query periods were examined between January 1, 2009 and December 31, 2010. A washout period of 0 days was used to estimate prevalent use. The maximum allowable treatment gap was set to 14 days, and the minimum episode duration and the minimum episode days supplied were set to zero days. The program was run for all users as well as those with pre-existing diagnosis codes falling into one of three groups: addiction, pain, or other. The pre-existing condition lookup period was set at 90 days from the drug index date. Age groups were split as follows: 0-17, 18-64, and 65+ years. In total, 96 different scenarios were examined in this report with differing query periods, pre-existing conditions, and drug product groups. See below for a description of each of these scenarios.

Scenario	Query Start Date	Query End Date	Incident Exposure	Drug/Exposure Criteria				Pre-Existing Condition Criteria				
				Washout (days)	Episode Duration (days)	Min Days Supplied	Episode Gap (days)	Pre-Existing Condition	Care Setting	Principal Dx?	Lookback Type	Lookback Period (days)
1	1/1/2009	12/31/2009	Buprenex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
2	1/1/2009	12/31/2009	Butrans	0	0	0	14	Overall**	Outpatient	No	Fixed	90
3	1/1/2009	12/31/2009	Suboxone	0	0	0	14	Overall**	Outpatient	No	Fixed	90
4	1/1/2009	12/31/2009	Subutex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
5	1/1/2009	12/31/2009	Generic Buprenorphine - Injectable	0	0	0	14	Overall**	Outpatient	No	Fixed	90
6	1/1/2009	12/31/2009	Generic Buprenorphine - Oral	0	0	0	14	Overall**	Outpatient	No	Fixed	90
7	1/1/2009	12/31/2009	Generic Buprenorphine - Powder	0	0	0	14	Overall**	Outpatient	No	Fixed	90
8	1/1/2009	12/31/2009	All*	0	0	0	14	Overall**	Outpatient	No	Fixed	90
9	1/1/2009	12/31/2009	Buprenex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
10	1/1/2009	12/31/2009	Butrans	0	0	0	14	Addiction	Outpatient	No	Fixed	90
11	1/1/2009	12/31/2009	Suboxone	0	0	0	14	Addiction	Outpatient	No	Fixed	90
12	1/1/2009	12/31/2009	Subutex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
13	1/1/2009	12/31/2009	Generic Buprenorphine - Injectable	0	0	0	14	Addiction	Outpatient	No	Fixed	90
14	1/1/2009	12/31/2009	Generic Buprenorphine - Oral	0	0	0	14	Addiction	Outpatient	No	Fixed	90
15	1/1/2009	12/31/2009	Generic Buprenorphine - Powder	0	0	0	14	Addiction	Outpatient	No	Fixed	90
16	1/1/2009	12/31/2009	All*	0	0	0	14	Addiction	Outpatient	No	Fixed	90
17	1/1/2009	12/31/2009	Buprenex	0	0	0	14	Pain	Outpatient	No	Fixed	90
18	1/1/2009	12/31/2009	Butrans	0	0	0	14	Pain	Outpatient	No	Fixed	90
19	1/1/2009	12/31/2009	Suboxone	0	0	0	14	Pain	Outpatient	No	Fixed	90
20	1/1/2009	12/31/2009	Subutex	0	0	0	14	Pain	Outpatient	No	Fixed	90
21	1/1/2009	12/31/2009	Generic Buprenorphine - Injectable	0	0	0	14	Pain	Outpatient	No	Fixed	90
22	1/1/2009	12/31/2009	Generic Buprenorphine - Oral	0	0	0	14	Pain	Outpatient	No	Fixed	90
23	1/1/2009	12/31/2009	Generic Buprenorphine - Powder	0	0	0	14	Pain	Outpatient	No	Fixed	90
24	1/1/2009	12/31/2009	All*	0	0	0	14	Pain	Outpatient	No	Fixed	90
25	1/1/2009	12/31/2009	Buprenex	0	0	0	14	Other	Outpatient	No	Fixed	90
26	1/1/2009	12/31/2009	Butrans	0	0	0	14	Other	Outpatient	No	Fixed	90
27	1/1/2009	12/31/2009	Suboxone	0	0	0	14	Other	Outpatient	No	Fixed	90
28	1/1/2009	12/31/2009	Subutex	0	0	0	14	Other	Outpatient	No	Fixed	90
29	1/1/2009	12/31/2009	Generic Buprenorphine - Injectable	0	0	0	14	Other	Outpatient	No	Fixed	90
30	1/1/2009	12/31/2009	Generic Buprenorphine - Oral	0	0	0	14	Other	Outpatient	No	Fixed	90

Modular Program Specifications cont.

31	1/1/2009	12/31/2009	Generic Buprenorphine - Powder	0	0	0	14	Other	Outpatient	No	Fixed	90
32	1/1/2009	12/31/2009	All*	0	0	0	14	Other	Outpatient	No	Fixed	90
33	1/1/2010	12/31/2010	Buprenex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
34	1/1/2010	12/31/2010	Butrans	0	0	0	14	Overall**	Outpatient	No	Fixed	90
35	1/1/2010	12/31/2010	Suboxone	0	0	0	14	Overall**	Outpatient	No	Fixed	90
36	1/1/2010	12/31/2010	Subutex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
37	1/1/2010	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Overall**	Outpatient	No	Fixed	90
38	1/1/2010	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Overall**	Outpatient	No	Fixed	90
39	1/1/2010	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Overall**	Outpatient	No	Fixed	90
40	1/1/2010	12/31/2010	All*	0	0	0	14	Overall**	Outpatient	No	Fixed	90
41	1/1/2010	12/31/2010	Buprenex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
42	1/1/2010	12/31/2010	Butrans	0	0	0	14	Overall**	Outpatient	No	Fixed	90
43	1/1/2010	12/31/2010	Suboxone	0	0	0	14	Addiction	Outpatient	No	Fixed	90
44	1/1/2010	12/31/2010	Subutex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
45	1/1/2010	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Addiction	Outpatient	No	Fixed	90
46	1/1/2010	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Addiction	Outpatient	No	Fixed	90
47	1/1/2010	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Addiction	Outpatient	No	Fixed	90
48	1/1/2010	12/31/2010	All*	0	0	0	14	Addiction	Outpatient	No	Fixed	90
49	1/1/2010	12/31/2010	Buprenex	0	0	0	14	Pain	Outpatient	No	Fixed	90
50	1/1/2010	12/31/2010	Butrans	0	0	0	14	Pain	Outpatient	No	Fixed	90
51	1/1/2010	12/31/2010	Suboxone	0	0	0	14	Pain	Outpatient	No	Fixed	90
52	1/1/2010	12/31/2010	Subutex	0	0	0	14	Pain	Outpatient	No	Fixed	90
53	1/1/2010	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Pain	Outpatient	No	Fixed	90
54	1/1/2010	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Pain	Outpatient	No	Fixed	90
55	1/1/2010	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Pain	Outpatient	No	Fixed	90
56	1/1/2010	12/31/2010	All*	0	0	0	14	Pain	Outpatient	No	Fixed	90
57	1/1/2010	12/31/2010	Buprenex	0	0	0	14	Other	Outpatient	No	Fixed	90
58	1/1/2010	12/31/2010	Butrans	0	0	0	14	Other	Outpatient	No	Fixed	90
59	1/1/2010	12/31/2010	Suboxone	0	0	0	14	Other	Outpatient	No	Fixed	90
60	1/1/2010	12/31/2010	Subutex	0	0	0	14	Other	Outpatient	No	Fixed	90
61	1/1/2010	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Other	Outpatient	No	Fixed	90
62	1/1/2010	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Other	Outpatient	No	Fixed	90
63	1/1/2010	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Other	Outpatient	No	Fixed	90
64	1/1/2010	12/31/2010	All*	0	0	0	14	Other	Outpatient	No	Fixed	90
65	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
66	1/1/2009	12/31/2010	Butrans	0	0	0	14	Overall**	Outpatient	No	Fixed	90
67	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Overall**	Outpatient	No	Fixed	90
68	1/1/2009	12/31/2010	Subutex	0	0	0	14	Overall**	Outpatient	No	Fixed	90
69	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Overall**	Outpatient	No	Fixed	90
70	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Overall**	Outpatient	No	Fixed	90
71	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Overall**	Outpatient	No	Fixed	90

Modular Program Specifications cont.

72	1/1/2009	12/31/2010	All*	0	0	0	14	Overall**	Outpatient	No	Fixed	90
73	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
74	1/1/2009	12/31/2010	Butrans	0	0	0	14	Addiction	Outpatient	No	Fixed	90
75	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Addiction	Outpatient	No	Fixed	90
76	1/1/2009	12/31/2010	Subutex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
77	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Addiction	Outpatient	No	Fixed	90
78	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Addiction	Outpatient	No	Fixed	90
79	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Addiction	Outpatient	No	Fixed	90
80	1/1/2009	12/31/2010	All*	0	0	0	14	Addiction	Outpatient	No	Fixed	90
81	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Pain	Outpatient	No	Fixed	90
82	1/1/2009	12/31/2010	Butrans	0	0	0	14	Pain	Outpatient	No	Fixed	90
83	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Pain	Outpatient	No	Fixed	90
84	1/1/2009	12/31/2010	Subutex	0	0	0	14	Pain	Outpatient	No	Fixed	90
85	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Pain	Outpatient	No	Fixed	90
86	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Pain	Outpatient	No	Fixed	90
87	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Pain	Outpatient	No	Fixed	90
88	1/1/2009	12/31/2010	All*	0	0	0	14	Pain	Outpatient	No	Fixed	90
89	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Other	Outpatient	No	Fixed	90
90	1/1/2009	12/31/2010	Butrans	0	0	0	14	Other	Outpatient	No	Fixed	90
91	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Other	Outpatient	No	Fixed	90
92	1/1/2009	12/31/2010	Subutex	0	0	0	14	Other	Outpatient	No	Fixed	90
93	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Other	Outpatient	No	Fixed	90
94	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Other	Outpatient	No	Fixed	90
95	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Other	Outpatient	No	Fixed	90
96	1/1/2009	12/31/2010	All*	0	0	0	14	Other	Outpatient	No	Fixed	90

*Includes all 7 Buprenorphine products

**No Pre-Existing Condition Criteria Designated for Overall Category

Table 1a. Number and Percent of New Users between January 1, 2009 and December 31, 2010 by Drug Product and Pre-Existing Condition Category

Drug Product	Pre-Existing Condition							
	Overall*		Addiction		Pain		Other	
	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall
<i>All Buprenorphine Products</i>	66,041	100.0%	25,041	37.9%	15,565	23.6%	8,923	13.5%
Buprenex	70	100.0%	6	8.6%	21	30.0%	7	10.0%
Butrans	0	---	0	---	0	---	0	---
Suboxone	62,844	100.0%	24,391	38.8%	14,764	23.5%	8,586	13.7%
Subutex	5,134	100.0%	1,797	35.0%	1,412	27.5%	787	15.3%
Generic Buprenorphine - Injectable	50	100.0%	8	16.0%	13	26.0%	6	12.0%
Generic Buprenorphine - Oral	4,411	100.0%	1,677	38.0%	1,260	28.6%	774	17.5%
Generic Buprenorphine - Powder	30	100.0%	4	13.3%	12	40.0%	1	3.3%

*No pre-existing condition criteria designated for Overall category

Table 1b. Number and Percent of New Users in 2009 by Drug Product and Pre-Existing Condition Category

Drug Product	Pre-Existing Condition							
	Overall*		Addiction		Pain		Other	
	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall
<i>All Buprenorphine Products</i>	42,262	100.0%	15,318	36.2%	9,249	21.9%	5,307	12.6%
Buprenex	58	100.0%	5	8.6%	17	29.3%	7	12.1%
Butrans	0	---	0	---	0	---	0	---
Suboxone	40,158	100.0%	14,883	37.1%	8,750	21.8%	5,103	12.7%
Subutex	4,044	100.0%	1,347	33.3%	1,057	26.1%	580	14.3%
Generic Buprenorphine - Injectable	37	100.0%	7	18.9%	7	18.9%	5	13.5%
Generic Buprenorphine - Oral	980	100.0%	373	38.1%	280	28.6%	177	18.1%
Generic Buprenorphine - Powder	21	100.0%	1	4.8%	7	33.3%	0	0.0%

*No pre-existing condition criteria designated for Overall category

Table 1c. Number and Percent of New Users in 2010 by Drug Product and Pre-Existing Condition Category

Drug Product	Pre-Existing Condition							
	Overall*		Addiction		Pain		Other	
	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall	New Users	% of Overall
<i>All Buprenorphine Products</i>	45,622	100.0%	20,586	45.1%	11,413	25.0%	7,318	16.0%
Buprenex	41	100.0%	4	9.8%	19	46.3%	1	2.4%
Butrans	0	---	0	---	0	---	0	---
Suboxone	43,092	100.0%	19,865	46.1%	10,682	24.8%	6,947	16.1%
Subutex	2,054	100.0%	815	39.7%	631	30.7%	375	18.3%
Generic Buprenorphine - Injectable	21	100.0%	1	4.8%	7	33.3%	1	4.8%
Generic Buprenorphine - Oral	4,054	100.0%	1,545	38.1%	1,145	28.2%	699	17.2%
Generic Buprenorphine - Powder	19	100.0%	3	15.8%	8	42.1%	2	10.5%

*No pre-existing condition criteria designated for Overall category

Table 2a. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		66,041	518,985	11,584,333	25,041	195,481	4,191,558
	Age Group	0 to 17 years	281	1,139	21,452	136	686	13,654
		18 to 64 years	65,034	514,069	11,471,015	24,651	193,310	4,143,218
		65+ years	726	3,777	91,866	254	1,485	34,686
	Sex	Female	25,547	194,629	4,327,064	10,248	77,050	1,649,591
		Male	40,421	323,863	7,246,438	14,753	118,194	2,536,444
Unknown		73	493	10,831	40	237	5,523	
Buprenex	Total		70	927	17,870	6	59	1,023
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	61	845	16,298	6	59	1,023
		65+ years	9	82	1,572	0	0	0
	Sex	Female	35	562	9,816	2	9	139
		Male	35	365	8,054	4	50	884
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		62,844	484,565	10,868,666	24,391	186,850	4,030,778
	Age Group	0 to 17 years	268	1,069	20,162	130	638	12,617
		18 to 64 years	61,930	480,255	10,769,545	24,035	184,882	3,987,154
		65+ years	646	3,241	78,959	226	1,330	31,007
	Sex	Female	24,035	176,619	3,966,826	9,906	71,976	1,554,159
		Male	38,736	307,460	6,891,144	14,445	114,637	2,471,096
Unknown		73	486	10,696	40	237	5,523	
Subutex	Total		5,134	19,648	405,445	1,797	6,748	125,977
	Age Group	0 to 17 years	19	38	666	9	22	489
		18 to 64 years	5,035	19,327	397,657	1,755	6,621	122,890
		65+ years	80	283	7,122	33	105	2,598
	Sex	Female	2,458	10,060	205,067	928	3,933	75,435
		Male	2,674	9,574	200,055	869	2,815	50,542
Unknown		2	14	323	0	0	0	

Table 2a cont. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		50	167	2,790	8	8	81
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	44	141	2,352	8	8	81
		65+ years	6	26	438	0	0	0
	Sex	Female	23	48	614	3	3	9
		Male	27	119	2,176	5	5	72
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,411	16,510	329,956	1,677	5,904	120,813
	Age Group	0 to 17 years	8	9	86	5	5	46
		18 to 64 years	4,345	16,321	325,391	1,649	5,818	118,801
		65+ years	58	180	4,479	23	81	1,966
	Sex	Female	2,097	8,590	163,583	847	3,315	66,879
		Male	2,311	7,917	166,323	827	2,586	53,884
Unknown		3	3	50	3	3	50	
Generic Buprenorphine - Powder	<i>Total</i>		30	204	4,656	4	42	761
	Age Group	0 to 17 years	3	3	68	0	0	0
		18 to 64 years	27	201	4,588	4	42	761
		65+ years	0	0	0	0	0	0
	Sex	Female	14	94	2,149	1	1	25
		Male	16	110	2,507	3	41	736
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 2b. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Pain

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		66,041	518,985	11,584,333	15,565	101,841	2,188,716
	Age Group	0 to 17 years	281	1,139	21,452	31	122	1,992
		18 to 64 years	65,034	514,069	11,471,015	15,155	100,039	2,148,792
		65+ years	726	3,777	91,866	379	1,680	37,932
	Sex	Female	25,547	194,629	4,327,064	7,531	47,383	1,015,966
		Male	40,421	323,863	7,246,438	8,019	54,388	1,171,304
Unknown		73	493	10,831	15	70	1,446	
Buprenex	Total		70	927	17,870	21	219	4,921
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	61	845	16,298	17	171	3,890
		65+ years	9	82	1,572	4	48	1,031
	Sex	Female	35	562	9,816	8	86	1,969
		Male	35	365	8,054	13	133	2,952
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		62,844	484,565	10,868,666	14,764	94,858	2,050,272
	Age Group	0 to 17 years	268	1,069	20,162	29	119	1,954
		18 to 64 years	61,930	480,255	10,769,545	14,402	93,296	2,015,627
		65+ years	646	3,241	78,959	333	1,443	32,691
	Sex	Female	24,035	176,619	3,966,826	7,070	43,027	931,426
		Male	38,736	307,460	6,891,144	7,679	51,761	1,117,400
Unknown		73	486	10,696	15	70	1,446	
Subutex	Total		5,134	19,648	405,445	1,412	4,558	87,071
	Age Group	0 to 17 years	19	38	666	2	4	95
		18 to 64 years	5,035	19,327	397,657	1,365	4,447	84,624
		65+ years	80	283	7,122	45	107	2,352
	Sex	Female	2,458	10,060	205,067	760	2,636	50,247
		Male	2,674	9,574	200,055	651	1,915	36,608
Unknown		2	14	323	1	7	216	

Table 2b cont. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Pain

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		50	167	2,790	13	28	314
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	44	141	2,352	10	22	187
		65+ years	6	26	438	3	6	127
	Sex	Female	23	48	614	9	24	215
		Male	27	119	2,176	4	4	99
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,411	16,510	329,956	1,260	4,280	86,224
	Age Group	0 to 17 years	8	9	86	2	2	33
		18 to 64 years	4,345	16,321	325,391	1,218	4,153	83,036
		65+ years	58	180	4,479	40	125	3,155
	Sex	Female	2,097	8,590	163,583	659	2,361	46,994
		Male	2,311	7,917	166,323	599	1,917	39,210
Unknown		3	3	50	2	2	20	
Generic Buprenorphine - Powder	<i>Total</i>		30	204	4,656	12	94	2,493
	Age Group	0 to 17 years	3	3	68	0	0	0
		18 to 64 years	27	201	4,588	12	94	2,493
		65+ years	0	0	0	0	0	0
	Sex	Female	14	94	2,149	8	46	1,188
		Male	16	110	2,507	4	48	1,305
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 2c. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Other

Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		66,041	518,985	11,584,333	8,923	62,452	1,305,088
	Age Group	0 to 17 years	281	1,139	21,452	63	357	6,427
		18 to 64 years	65,034	514,069	11,471,015	8,734	61,397	1,282,979
		65+ years	726	3,777	91,866	126	698	15,682
	Sex	Female	25,547	194,629	4,327,064	4,272	29,601	606,901
		Male	40,421	323,863	7,246,438	4,630	32,751	696,184
Unknown		73	493	10,831	21	100	2,003	
Buprenex	Total		70	927	17,870	7	26	492
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	61	845	16,298	7	26	492
		65+ years	9	82	1,572	0	0	0
	Sex	Female	35	562	9,816	2	3	40
		Male	35	365	8,054	5	23	452
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		62,844	484,565	10,868,666	8,586	58,854	1,237,571
	Age Group	0 to 17 years	268	1,069	20,162	61	327	5,699
		18 to 64 years	61,930	480,255	10,769,545	8,412	57,908	1,218,145
		65+ years	646	3,241	78,959	113	619	13,727
	Sex	Female	24,035	176,619	3,966,826	4,104	27,441	568,117
		Male	38,736	307,460	6,891,144	4,461	31,313	667,451
Unknown		73	486	10,696	21	100	2,003	
Subutex	Total		5,134	19,648	405,445	787	2,814	52,130
	Age Group	0 to 17 years	19	38	666	6	18	386
		18 to 64 years	5,035	19,327	397,657	770	2,764	50,899
		65+ years	80	283	7,122	11	32	845
	Sex	Female	2,458	10,060	205,067	404	1,626	29,695
		Male	2,674	9,574	200,055	383	1,188	22,435
Unknown		2	14	323	0	0	0	

Table 2c cont. Number of New Users, Dispensings, and Total Days Supplied in 2009-2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Other

Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		50	167	2,790	6	7	45
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	44	141	2,352	6	7	45
		65+ years	6	26	438	0	0	0
	Sex	Female	23	48	614	3	4	8
		Male	27	119	2,176	3	3	37
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,411	16,510	329,956	774	2,735	55,517
	Age Group	0 to 17 years	8	9	86	1	1	30
		18 to 64 years	4,345	16,321	325,391	763	2,716	55,157
		65+ years	58	180	4,479	10	18	330
	Sex	Female	2,097	8,590	163,583	384	1,362	26,802
		Male	2,311	7,917	166,323	388	1,371	28,695
Unknown		3	3	50	2	2	20	
Generic Buprenorphine - Powder	<i>Total</i>		30	204	4,656	1	1	60
	Age Group	0 to 17 years	3	3	68	0	0	0
		18 to 64 years	27	201	4,588	1	1	60
		65+ years	0	0	0	0	0	0
	Sex	Female	14	94	2,149	0	0	0
		Male	16	110	2,507	1	1	60
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 3a. Number of New Users, Dispensings, and Total Days Supplied in 2009 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		42,262	381,894	8,765,533	15,318	140,984	3,125,946
	Age Group	0 to 17 years	184	814	15,221	87	487	9,482
		18 to 64 years	41,616	378,329	8,681,671	15,088	139,456	3,090,604
		65+ years	462	2,751	68,641	143	1,041	25,860
	Sex	Female	16,087	141,414	3,240,062	6,098	54,150	1,197,168
		Male	26,131	240,136	5,517,779	9,197	86,663	1,924,586
Unknown		44	344	7,692	23	171	4,192	
Buprenex	Total		58	784	15,305	5	51	886
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	49	702	13,733	5	51	886
		65+ years	9	82	1,572	0	0	0
	Sex	Female	27	455	8,164	1	1	2
		Male	31	329	7,141	4	50	884
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		40,158	357,017	8,226,991	14,883	134,969	3,010,684
	Age Group	0 to 17 years	175	753	14,033	82	443	8,500
		18 to 64 years	39,579	353,929	8,154,612	14,677	133,592	2,979,058
		65+ years	404	2,335	58,346	124	934	23,126
	Sex	Female	15,109	128,471	2,968,695	5,879	50,575	1,128,406
		Male	25,006	228,209	5,250,711	8,981	84,223	1,878,086
Unknown		43	337	7,585	23	171	4,192	
Subutex	Total		4,044	16,700	354,630	1,347	5,389	104,425
	Age Group	0 to 17 years	17	34	573	8	19	399
		18 to 64 years	3,965	16,419	347,606	1,314	5,274	101,622
		65+ years	62	247	6,451	25	96	2,404
	Sex	Female	1,928	8,572	178,689	699	3,193	63,331
		Male	2,115	8,121	175,834	648	2,196	41,094
Unknown		1	7	107	0	0	0	

Table 3a cont. Number of New Users, Dispensings, and Total Days Supplied in 2009 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		37	132	2,286	7	7	51
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	33	110	1,893	7	7	51
		65+ years	4	22	393	0	0	0
	Sex	Female	16	25	368	3	3	9
		Male	21	107	1,918	4	4	42
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		980	4,155	91,222	373	1,659	37,932
	Age Group	0 to 17 years	4	4	39	3	3	13
		18 to 64 years	970	4,137	90,848	368	1,650	37,769
		65+ years	6	14	335	2	6	150
	Sex	Female	464	2,121	43,828	191	899	19,362
		Male	515	2,033	47,394	181	759	18,570
Unknown		1	1	0	1	1	0	
Generic Buprenorphine - Powder	<i>Total</i>		21	169	4,115	1	17	463
	Age Group	0 to 17 years	2	2	38	0	0	0
		18 to 64 years	19	167	4,077	1	17	463
		65+ years	0	0	0	0	0	0
	Sex	Female	10	86	1,941	0	0	0
		Male	11	83	2,174	1	17	463
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		42,262	381,894	8,765,533	9,249	69,241	1,538,675
	Age Group	0 to 17 years	184	814	15,221	23	99	1,463
		18 to 64 years	41,616	378,329	8,681,671	8,999	68,045	1,511,873
		65+ years	462	2,751	68,641	227	1,097	25,339
	Sex	Female	16,087	141,414	3,240,062	4,386	31,259	695,465
		Male	26,131	240,136	5,517,779	4,852	37,930	842,003
Unknown		44	344	7,692	11	52	1,207	
Buprenex	Total		58	784	15,305	17	196	4,341
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	49	702	13,733	13	148	3,310
		65+ years	9	82	1,572	4	48	1,031
	Sex	Female	27	455	8,164	7	78	1,832
		Male	31	329	7,141	10	118	2,509
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		40,158	357,017	8,226,991	8,750	64,665	1,443,217
	Age Group	0 to 17 years	175	753	14,033	22	98	1,458
		18 to 64 years	39,579	353,929	8,154,612	8,532	63,614	1,419,506
		65+ years	404	2,335	58,346	196	953	22,253
	Sex	Female	15,109	128,471	2,968,695	4,110	28,376	636,682
		Male	25,006	228,209	5,250,711	4,629	36,237	805,328
Unknown		43	337	7,585	11	52	1,207	
Subutex	Total		4,044	16,700	354,630	1,057	3,680	71,823
	Age Group	0 to 17 years	17	34	573	1	1	5
		18 to 64 years	3,965	16,419	347,606	1,022	3,589	69,870
		65+ years	62	247	6,451	34	90	1,948
	Sex	Female	1,928	8,572	178,689	565	2,105	40,932
		Male	2,115	8,121	175,834	492	1,575	30,891
Unknown		1	7	107	0	0	0	

Table 3b cont. Number of New Users, Dispensings, and Total Days Supplied in 2009 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition - Pain

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		37	132	2,286	7	9	131
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	33	110	1,893	5	6	34
		65+ years	4	22	393	2	3	97
	Sex	Female	16	25	368	6	8	101
		Male	21	107	1,918	1	1	30
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		980	4,155	91,222	280	1,105	25,283
	Age Group	0 to 17 years	4	4	39	0	0	0
		18 to 64 years	970	4,137	90,848	276	1,100	25,163
		65+ years	6	14	335	4	5	120
	Sex	Female	464	2,121	43,828	139	597	12,665
		Male	515	2,033	47,394	140	507	12,618
Unknown		1	1	0	1	1	0	
Generic Buprenorphine - Powder	<i>Total</i>		21	169	4,115	7	85	2,255
	Age Group	0 to 17 years	2	2	38	0	0	0
		18 to 64 years	19	167	4,077	7	85	2,255
		65+ years	0	0	0	0	0	0
	Sex	Female	10	86	1,941	4	38	980
		Male	11	83	2,174	3	47	1,275
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 3c. Number of New Users, Dispensings, and Total Days Supplied in 2009 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition -								
Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
<i>All Buprenorphine Products</i>	<i>Total</i>		42,262	381,894	8,765,533	5,307	42,919	926,209
	Age Group	0 to 17 years	184	814	15,221	41	277	4,890
		18 to 64 years	41,616	378,329	8,681,671	5,197	42,175	910,020
		65+ years	462	2,751	68,641	69	467	11,299
	Sex	Female	16,087	141,414	3,240,062	2,500	19,881	416,542
		Male	26,131	240,136	5,517,779	2,796	22,969	508,403
Unknown		44	344	7,692	11	69	1,264	
Buprenex	<i>Total</i>		58	784	15,305	7	26	492
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	49	702	13,733	7	26	492
		65+ years	9	82	1,572	0	0	0
	Sex	Female	27	455	8,164	2	3	40
		Male	31	329	7,141	5	23	452
Unknown		0	0	0	0	0	0	
Butrans	<i>Total</i>		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	<i>Total</i>		40,158	357,017	8,226,991	5,103	40,522	879,417
	Age Group	0 to 17 years	175	753	14,033	40	248	4,192
		18 to 64 years	39,579	353,929	8,154,612	5,000	39,845	864,981
		65+ years	404	2,335	58,346	63	429	10,244
	Sex	Female	15,109	128,471	2,968,695	2,405	18,425	389,775
		Male	25,006	228,209	5,250,711	2,687	22,028	488,378
Unknown		43	337	7,585	11	69	1,264	
Subutex	<i>Total</i>		4,044	16,700	354,630	580	2,313	44,251
	Age Group	0 to 17 years	17	34	573	5	15	296
		18 to 64 years	3,965	16,419	347,606	568	2,271	43,215
		65+ years	62	247	6,451	7	27	740
	Sex	Female	1,928	8,572	178,689	297	1,336	25,112
		Male	2,115	8,121	175,834	283	977	19,139
Unknown		1	7	107	0	0	0	

Table 3c cont. Number of New Users, Dispensings, and Total Days Supplied in 2009 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition - Other

Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		37	132	2,286	5	5	39
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	33	110	1,893	5	5	39
		65+ years	4	22	393	0	0	0
	Sex	Female	16	25	368	2	2	2
		Male	21	107	1,918	3	3	37
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		980	4,155	91,222	177	755	17,689
	Age Group	0 to 17 years	4	4	39	0	0	0
		18 to 64 years	970	4,137	90,848	175	753	17,629
		65+ years	6	14	335	2	2	60
	Sex	Female	464	2,121	43,828	80	297	7,024
		Male	515	2,033	47,394	96	457	10,665
Unknown		1	1	0	1	1	0	
Generic Buprenorphine - Powder	<i>Total</i>		21	169	4,115	0	0	0
	Age Group	0 to 17 years	2	2	38	0	0	0
		18 to 64 years	19	167	4,077	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	10	86	1,941	0	0	0
		Male	11	83	2,174	0	0	0
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 4a. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		45,622	326,886	7,398,529	20,586	153,952	3,450,098
	Age Group	0 to 17 years	114	396	7,890	56	233	4,953
		18 to 64 years	44,988	323,765	7,323,011	20,323	152,578	3,417,715
		65+ years	520	2,725	67,628	207	1,141	27,430
	Sex	Female	17,787	124,416	2,788,864	8,280	60,075	1,337,480
		Male	27,783	202,154	4,602,113	12,277	93,733	2,109,055
Unknown		52	316	7,552	29	144	3,563	
Buprenex	Total		41	455	8,515	4	80	1,348
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	37	414	8,105	4	80	1,348
		65+ years	4	41	410	0	0	0
	Sex	Female	24	303	4,892	2	50	940
		Male	17	152	3,623	2	30	408
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		43,092	301,723	6,876,367	19,865	145,176	3,270,748
	Age Group	0 to 17 years	110	387	7,788	55	229	4,898
		18 to 64 years	42,511	298,964	6,809,390	19,620	143,918	3,241,490
		65+ years	471	2,372	59,189	190	1,029	24,360
	Sex	Female	16,560	111,506	2,532,109	7,889	55,072	1,234,369
		Male	26,480	189,909	4,336,952	11,947	89,960	2,032,816
Unknown		52	308	7,306	29	144	3,563	
Subutex	Total		2,054	7,365	150,020	815	3,305	62,945
	Age Group	0 to 17 years	2	4	93	1	3	90
		18 to 64 years	2,016	7,254	147,328	798	3,268	61,941
		65+ years	36	107	2,599	16	34	914
	Sex	Female	1,009	3,715	76,482	429	1,910	37,636
		Male	1,044	3,643	73,322	386	1,395	25,309
Unknown		1	7	216	0	0	0	

Table 4a cont. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Addiction

Drug Product		Overall*			Addiction			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		21	54	817	1	1	30
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	17	46	742	1	1	30
		65+ years	4	8	75	0	0	0
	Sex	Female	10	35	429	0	0	0
		Male	11	19	388	1	1	30
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,054	15,882	321,695	1,545	5,632	117,312
	Age Group	0 to 17 years	4	5	47	2	2	33
		18 to 64 years	3,994	15,690	316,934	1,521	5,552	115,403
		65+ years	56	187	4,714	22	78	1,876
	Sex	Female	1,944	8,259	158,259	785	3,188	65,606
		Male	2,108	7,621	163,386	758	2,442	51,656
Unknown		2	2	50	2	2	50	
Generic Buprenorphine - Powder	<i>Total</i>		19	118	2,660	3	25	298
	Age Group	0 to 17 years	1	1	30	0	0	0
		18 to 64 years	18	117	2,630	3	25	298
		65+ years	0	0	0	0	0	0
	Sex	Female	9	53	1,247	1	1	25
		Male	10	65	1,413	2	24	273
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 4b. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Pain

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		45,622	326,886	7,398,529	11,413	72,853	1,621,196
	Age Group	0 to 17 years	114	396	7,890	9	24	544
		18 to 64 years	44,988	323,765	7,323,011	11,126	71,420	1,586,820
		65+ years	520	2,725	67,628	278	1,409	33,832
	Sex	Female	17,787	124,416	2,788,864	5,472	33,903	743,718
		Male	27,783	202,154	4,602,113	5,934	38,927	877,102
Unknown		52	316	7,552	7	23	376	
Buprenex	Total		41	455	8,515	19	209	3,883
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	37	414	8,105	17	179	3,610
		65+ years	4	41	410	2	30	273
	Sex	Female	24	303	4,892	11	119	1,941
		Male	17	152	3,623	8	90	1,942
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		43,092	301,723	6,876,367	10,682	66,020	1,479,948
	Age Group	0 to 17 years	110	387	7,788	8	22	511
		18 to 64 years	42,511	298,964	6,809,390	10,424	64,821	1,451,058
		65+ years	471	2,372	59,189	250	1,177	28,379
	Sex	Female	16,560	111,506	2,532,109	5,054	29,858	659,629
		Male	26,480	189,909	4,336,952	5,621	36,139	819,943
Unknown		52	308	7,306	7	23	376	
Subutex	Total		2,054	7,365	150,020	631	2,174	44,756
	Age Group	0 to 17 years	2	4	93	1	3	90
		18 to 64 years	2,016	7,254	147,328	611	2,102	42,846
		65+ years	36	107	2,599	19	69	1,820
	Sex	Female	1,009	3,715	76,482	347	1,254	26,462
		Male	1,044	3,643	73,322	283	913	18,078
Unknown		1	7	216	1	7	216	

Table 4b cont. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Pain

Drug Product		Overall*			Pain			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		21	54	817	7	21	183
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	17	46	742	5	16	153
		65+ years	4	8	75	2	5	30
	Sex	Female	10	35	429	4	18	114
		Male	11	19	388	3	3	69
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,054	15,882	321,695	1,145	4,049	82,253
	Age Group	0 to 17 years	4	5	47	2	2	33
		18 to 64 years	3,994	15,690	316,934	1,105	3,912	78,740
		65+ years	56	187	4,714	38	135	3,480
	Sex	Female	1,944	8,259	158,259	609	2,319	46,877
		Male	2,108	7,621	163,386	535	1,729	35,356
Unknown		2	2	50	1	1	20	
Generic Buprenorphine - Powder	<i>Total</i>		19	118	2,660	8	53	1,272
	Age Group	0 to 17 years	1	1	30	0	0	0
		18 to 64 years	18	117	2,630	8	53	1,272
		65+ years	0	0	0	0	0	0
	Sex	Female	9	53	1,247	6	37	837
		Male	10	65	1,413	2	16	435
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 4c. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Other

Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
All Buprenorphine Products	Total		45,622	326,886	7,398,529	7,318	49,630	1,095,166
	Age Group	0 to 17 years	114	396	7,890	25	96	2,017
		18 to 64 years	44,988	323,765	7,323,011	7,199	49,019	1,081,932
		65+ years	520	2,725	67,628	94	515	11,217
	Sex	Female	17,787	124,416	2,788,864	3,414	23,011	506,405
		Male	27,783	202,154	4,602,113	3,891	26,555	587,054
Unknown		52	316	7,552	13	64	1,707	
Buprenex	Total		41	455	8,515	1	1	30
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	37	414	8,105	1	1	30
		65+ years	4	41	410	0	0	0
	Sex	Female	24	303	4,892	0	0	0
		Male	17	152	3,623	1	1	30
Unknown		0	0	0	0	0	0	
Butrans	Total		0	0	0	0	0	0
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	0	0	0	0	0	0
		65+ years	0	0	0	0	0	0
	Sex	Female	0	0	0	0	0	0
		Male	0	0	0	0	0	0
Unknown		0	0	0	0	0	0	
Suboxone	Total		43,092	301,723	6,876,367	6,947	46,039	1,020,480
	Age Group	0 to 17 years	110	387	7,788	24	95	1,987
		18 to 64 years	42,511	298,964	6,809,390	6,840	45,525	1,009,702
		65+ years	471	2,372	59,189	83	419	8,791
	Sex	Female	16,560	111,506	2,532,109	3,226	20,978	464,038
		Male	26,480	189,909	4,336,952	3,708	24,997	554,735
Unknown		52	308	7,306	13	64	1,707	
Subutex	Total		2,054	7,365	150,020	375	1,330	26,963
	Age Group	0 to 17 years	2	4	93	1	3	90
		18 to 64 years	2,016	7,254	147,328	366	1,291	25,957
		65+ years	36	107	2,599	8	36	916
	Sex	Female	1,009	3,715	76,482	198	763	16,129
		Male	1,044	3,643	73,322	177	567	10,834
Unknown		1	7	216	0	0	0	

Table 4c cont. Number of New Users, Dispensings, and Total Days Supplied in 2010 by Drug Product, Age Group, and Sex Overall and for Pre-Existing Condition Category - Other

Drug Product		Overall*			Other			
		New Users	Dispensings	Total Days Supplied	New Users	Dispensings	Total Days Supplied	
Generic Buprenorphine - Injectable	<i>Total</i>		21	54	817	1	2	6
	Age Group	0 to 17 years	0	0	0	0	0	0
		18 to 64 years	17	46	742	1	2	6
		65+ years	4	8	75	0	0	0
	Sex	Female	10	35	429	1	2	6
		Male	11	19	388	0	0	0
Unknown		0	0	0	0	0	0	
Generic Buprenorphine - Oral	<i>Total</i>		4,054	15,882	321,695	699	2,556	52,123
	Age Group	0 to 17 years	4	5	47	1	1	30
		18 to 64 years	3,994	15,690	316,934	689	2,526	51,438
		65+ years	56	187	4,714	9	29	655
	Sex	Female	1,944	8,259	158,259	351	1,339	26,762
		Male	2,108	7,621	163,386	347	1,216	25,341
Unknown		2	2	50	1	1	20	
Generic Buprenorphine - Powder	<i>Total</i>		19	118	2,660	2	2	75
	Age Group	0 to 17 years	1	1	30	0	0	0
		18 to 64 years	18	117	2,630	2	2	75
		65+ years	0	0	0	0	0	0
	Sex	Female	9	53	1,247	0	0	0
		Male	10	65	1,413	2	2	75
Unknown		0	0	0	0	0	0	

*No pre-existing condition criteria designated for Overall category

Table 5. Number of New Users, Enrollees, and New Users per 100,000 Enrollees by Year, Pre-Existing Condition Category, and Drug Product									
		Year							
		2009				2010			
Drug Product		Overall*	Pre-existing - Addiction	Pre-existing - Pain	Pre-existing - Other	Overall*	Pre-existing - Addiction	Pre-existing - Pain	Pre-existing - Other
All Buprenorphine Products	New Users	42,262	15,318	9,249	5,307	45,622	20,586	11,413	7,318
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	New Users/100k Enrollees	93.7	34.0	20.5	11.8	104.2	47.0	26.1	16.7
Buprenex	New Users	58	5	17	7	41	4	19	1
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Butrans	New Users	0	0	0	0	0	0	0	0
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Suboxone	New Users	40,158	14,883	8,750	5,103	43,092	19,865	10,682	6,947
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	89.0	33.0	19.4	11.3	98.4	45.4	24.4	15.9
Subutex	New Users	4,044	1,347	1,057	580	2,054	815	631	375
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	9.0	3.0	2.3	1.3	4.7	1.9	1.4	0.9
Generic Buprenorphine - Injectable	New Users	37	7	7	5	21	1	7	1
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Buprenorphine - Oral	New Users	980	373	280	177	4,054	1,545	1,145	699
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	2.2	0.8	0.6	0.4	9.3	3.5	2.6	1.6
Generic Buprenorphine - Powder	New Users	21	1	7	0	19	3	8	2
	Number of Enrollees	45,103,516	45,103,516	45,103,516	45,103,516	43,790,907	43,790,907	43,790,907	43,790,907
	Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

*No pre-existing condition criteria designated for Overall category